Misconceptions Surrounding Hepatocellular Carcinoma

Saturday, January 5, 2019

Misconceptions Surrounding Hepatocellular Carcinoma

Clinical Liver Disease

Clinical Liver Disease is an official digital educational learning resource from the American Association for the Study of Liver Diseases. Visitors are able to view videos, access full text articles, and download files in either HTML or PDF formats.

Volume 12, Issue 6

Misconceptions Surrounding Hepatocellular Carcinoma

Nayantara Orekondy M.D.
Sheila Eswaran M.D.
Pages: 154-159

First Published:02 January 2019

Download PDF
View article online

In this article, we hope to dispel common misconceptions of HCC to improve the care of patients at risk for and diagnosed with HCC.
Misconception 1: Only Patients with Cirrhosis Need to Undergo Surveillance for HCC

Misconception 2: Liver Biopsy is Necessary to Diagnose HCC
Misconception 3: There is no Curative Therapy for HCC
Misconception 4: Patients with HCC are not Transplant Candidates
Misconception 5: Palliative Therapy does not Improve Survival in HCC

Misconception 6: No Effective Systemic

Continue to article:

https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/cld.752

Watch a video presentation of this article

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Contact hcvnewdrugs@gmail.com

Helpful Links
HCV Education
Research Articles
Fibrosis
Cirrhosis
Liver Cancer
Liver Transplants
Fatty Liver Disease
HCV-elderly
Possible Side Effects Of HCV Therapy
Other Conditions Related To HCV
HCV Genotypes/treatment
HCV Newsletters
Premier Hepatitis C Websites

The above links offer data about interferon-free regimens approved to treat HCV, with learning activities, editorials, and tips from patient bloggers who understand the ups and downs of liver disease, in addition to a list of outstanding hepatitis C websites, blogs and support forums.

On Twitter
I highly suggest you follow Henry E. Chang on Twitter if you are interested in reading articles about the treatment and management of hepatitis C.

The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"

Latest Update Feb 12, 2019

Lancet Study:

Direct-acting antivirals reduce risk of premature mortality and liver cancer for people with chronic hepatitis C

These findings firmly counter those of a Cochrane review of direct-acting antiviral treatment trials that could neither confirm nor reject if direct-acting antivirals had an effect on long-term HCV-related morbidity and mortality. They also provide the best evidence to date to support guidance documents that recommend direct-acting antiviral treatment for all patients with chronic HCV infection.

The Controversy
Rebuttal over Cochrane Review of DAAs
A systematic review published by the Cochrane Collaboration suggested achieving SVR (cure) for patients using hepatitis C direct-acting antivirals (DAAs) doesn't correlate with any long term benefits. View each rebuttal and all ongoing media coverage.